Table 3 Regression models of rise-in-WBCs from pre- to during CRRT and hospital mortality.

From: Change in platelet and leukocyte counts and hospital mortality in adults with acute kidney injury receiving continuous renal replacement therapy

Predictor

Rise-in-WBC SD groups

Rise-in-WBC percent change

 

Odd ratio (95% CI)

P-value

Odd ratio (95% CI)

P-value

Age

1.015 (1.006, 1.024)

< 0.01

1.015 (1.006, 1.024)

< 0.01

Charlson Comorbidity Index

1.063 (1.011, 1.119)

0.017

1.062 (1.010, 1.117)

0.019

Baseline serum creatinine

0.873 (0.799, 0.949)

< 0.01

0.871 (0.797, 0.947)

< 0.01

SOFA at ICU admission

1.068 (1.036, 1.102)

< 0.01

1.068 (1.036, 1.102)

< 0.01

SOFA at CRRT initiation

1.043 (1.014, 1.073)

< 0.01

1.04 (1.015, 1.074)

< 0.01

Rise in WBCs a during CRRT by SD groups b

    

 <1 SD (-59.15%)

1.546 (0.655, 3.764)

0.323

  

 >1 SD (135.45%)

1.408 (0.878, 2.297)

0.162

  

 Rise in WBCs during CRRT, by 10%

  

1.001 (0.999, 1.002)

0.455

  1. CI: confidence interval; SOFA: sequential organ failure assessment, ICU: intensive care unit, WBC: white blood cell, CRRT: Continuous renal replacement therapy, SD: standard deviation.
  2. a Change was calculated by the difference between the mean after CRRT minus before CRRT; a negative value indicated a drop in platelet/WBC count after CRRT initiation while a positive value indicated an increase in platelet/WBC counts after CRRT initiation.
  3. b Reference group was selected using the SD group with the lowest mortality rate after CRRT initiation.
Back to article page